IMvigor010 Primary Analysis from a Phase III Randomized Study of Adjuvant Atezolizumab versus Observation in High-Risk Muscle-Invasive Urothelial Carcinoma - Thomas Powles & Matthew Galsky

The current standard of care for patients with localized muscle-invasive bladder cancer involves neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. Unfortunately, even with chemotherapy and surgery, cancer recurrence is common, with a 5-year survival rate of 50—60%. Thus, additional strategies are necessary to help patients achieve long term survival. Thomas Powles and Matthew Galsky join Alicia Morgans to review the data presented at ASCO 2020 on IMvigor010 which tested the approach of the addition of immune checkpoint inhibitor atezolizumab as adjuvant immunotherapy following cystectomy. IMvigor010 is a global Phase III, open-label, randomized, controlled study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared to observation in 809 people with MIUC, who are at high risk for recurrence following resection. The primary endpoint is DFS as assessed by the investigator, which is defined as the time from randomization to invasive urothelial cancer recurrence or death. This study did not meet its primary endpoint of disease-free survival (DFS) since there was no significant difference in disease-free survival (DFS) between atezolizumab and observation. 


Matthew Galsky, MD Director of Genitourinary Medical Oncology, Tisch Cancer Institute, Professor of Medicine, Mount Sinai

Thomas Powles, MBBS, MRCP, MD, Professor of Genitourinary Oncology, Lead for Solid Tumour Research at Barts Cancer Institute, Director of Barts Cancer Institute, London, United Kingdom

Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.